Infection of an urachal cyst during etanercept therapy in juvenile idiopathic arthritis.

Etanercept, a tumor necrosis factor (TNF) receptor alpha antagonist is licensed for the treatment in patients affected by polyarticular juvenile idiopathic arthritis, who do not tolerate or had an inadequate response to methotrexate. Infections related to immunosuppression by etanercept are of major concern. We report on a 17-year-old boy with enthesitis-related arthritis who developed a major infection of an urachal cyst 18 months after initiation of etanercept therapy, which required surgery. The urachus had not been symptomatic before.
AuthorsA Holl-Wieden, M Beer, A Marx, R Bonfig, D Tappe, H J Girschick
JournalRheumatology international (Rheumatol Int) Vol. 28 Issue 8 Pg. 819-22 (Jun 2008) ISSN: 0172-8172 [Print] Germany
PMID18193232 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Etanercept
  • Adolescent
  • Arthritis, Juvenile (complications, drug therapy)
  • Biopsy
  • Child
  • Etanercept
  • Humans
  • Immunoglobulin G (therapeutic use)
  • Infection (complications)
  • Male
  • Receptors, Tumor Necrosis Factor (therapeutic use)
  • Urachal Cyst (complications, pathology, ultrasonography)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: